ContraFect Corporation (CFRX)

$3.1

+0.03 (+0.98%)
Rating:
Recommendation:
Buy
Symbol CFRX
Price $3.1
Beta 0.517
Volume Avg. 0.13M
Market Cap 121.931M
Shares () -
52 Week Range 2.11-4.54
1y Target Est -
DCF Unlevered CFRX DCF ->
DCF Levered CFRX LDCF ->
ROE -96.59% Strong Sell
ROA -81.79% Strong Sell
Operating Margin -
Debt / Equity 86.81% Buy
P/E -
P/B 4.06 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest CFRX news


Dr. Roger Pomerantz
Healthcare
Biotechnology
NASDAQ Capital Market

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia. The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis; and CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also initiated an expanded access program to provide Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.